Enrolled participants will be followed for up to 10 years depending on the time the participants are included after initiating teplizumab treatment.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment.
Participants must have a confirmed diagnosis of Stage 2 T1D according to the treating physician at the time of the first infusion of teplizumab.
(Note: Participants who progress to Stage 3 T1D by Week 6 will still be eligible, provided they were in Stage 2 at the time of the first teplizumab infusion.)
Participants (or their legal guardians, as applicable) who provide appropriate written or electronic informed consent/assent as applicable for the age of the participant and as per local regulations.
You may not be if
Participants who had participated in a previous clinical trial for teplizumab.
Participants enrolled in a clinical trial within 6 months prior to study enrollment.
(Note: Participants enrolled in other observational studies may be included.)
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
